【Objective】To establish a simple method for preparing tissue chip.【Methods】One hundred and thirty mammary cancer and intestinal cancer specimens were fixed by formaldehyde(40?g/L) and embedded by wax,and then were made into routine tissue slices and stained by haematoxylin and eosin(HE).Wax slices with tissue chip were prepared by fixing a tissue slice(0.1 cm in diameter)into the hole(0.2 cm in diameter and 2～4mm in depth) of a blank wax slice and were sliced into 4?m-thick slices.The tissue chips were mounted on the slide and stained by immunohistochemistry after treatment.【Results】A slide held 45 tissue chips and 130 specimens could be all detected only on 3 slides,which saved time and the amount of reagent.The immunohistochemical results showed that the positive location was accurate and the background was clear.【Conclusion】This method for preparing tissue chip is simple and effective,and can save the amount of reagent.It is easy for the comparative and separated detection of specimens.

We have studied mainly the distribution of this ~3H-labelled schistosomicidal drug in the livers and brains of the albino mice. In livers the ~3H-labelled substances were localized in greater quantity in the liver cell trabecula than in the sinusoids, and were taken up by the Kupffer's cells too. But the most prominent condense localization of the ~3H-labelled substances were in the interlobular bile ducts indicating that the original agent and its metabolites were excreted through the bile ducts system. The nuclei of the liver cells contained a certain amount lof the ~3H-labelled substances, about 7 silver grains in each nucleus with a diameter of about 10.7? seen in 2? thick freezing sections. One of the metabolites of this schistosomicidal drug being a mutagenic agent, the appearance of ~3H-labelled substances in the cell nuclei attracts our great attentions. As for the genesis mechanism of jaundice after administration of this schistosomicidal drug, our opinion is that it might be chiefly the result of drug sensitizied allergy reaction in accordance with a lot of works in the clinics, immunological test, pharmacological principles and our present studies. In the brains, the ~3H-labelled substances distributed much more in the white substances than in the gray substances, with the exception of the substantia nigra which had the same density of number of silver grains as the white substances. With these findingsthe clinical symptoms of the nervous system and their recovery were reviewed.

Paroxysmal sympathetic hyperactivity (PSH) is mainly secondary to a variety of acquired brain injuries, with the highest incidence of traumatic brain injury. Multiple symptoms such as paroxysmal tachycardia, shortness of breath, hypertension, hyperthermia and dystonia can occur simultaneously and repeatedly. The pathophysiological mechanism of PSH is complex. At present, drug treatment is mainly used to control symptoms; however, the combined use of multiple drugs will bring different degrees of toxic and side effects to multiple organs such as liver, kidney and lung while inhibiting sympathetic excitement. This paper mainly reviews the recent advance in non-drug treatment of PSH after craniocerebral injury from 4 aspects: nutritional support, hyperbaric oxygen therapy, avoidance of adverse stimulation and family support to standardize the PSH comprehensive management, and reduce episodes in order to improve prognosis and provide reference for clinical treatment.

Objective:To evaluate the immunogenicity and immune persistence of purified Vero cells rabies vaccine (PVRV) with Zagreb and Essen regimen.Methods:Prospective study: Patients with first Class II exposure to rabies were recruited from the Dog Injury Cinic of Guangxi Center for Disease Control and Prevention (Guangxi CDC) and randomly divided into the Zagreb (2-1-1) and Essen (1-1-1-1-1) regimen group. All patients were inoculated with the vaccines from the same manufacturer and batch, and 3 ml serum was collected at the 45th day and in 1-year, 2-year and 3-year after immunization. Rapid fluorescent inhibition test (RFFIT) was used to detect rabies virus neutralizing antibody (RVNA). The attenuation of RVNA positive rate and geometric mean titer (GMT) with time was analyzed. Retrospective study: The informed consents for rabies vaccine in the Dog Injury Clinic of Guangxi CDC were checked out. The patients who were injected with PVRV (same manufacturer but unlimited batch) but without passive immune agents for the first time within 3 years were selected and divided into 1-year, 2-year and 3-year group. Each group was further divided into Zagreb and Essen regimen group. The serum (3 ml) was collected at 1 year, 2 years and 3 years after immunization and detected the RVNA by RFFIT.Results:Prospective study: The RVNA positive rates on the 45th day and in 1-year, 2-year and 3-year after immunizationin in the Zagreb and Essen regimen group were 100%, 95%, 85%, 80% and 98.25%, 89.47%, 89.47%, 85.96%, respectively. There was no statistically significant difference in the RVNA positive rates at the same time point between the two regimen groups ( P>0.05). The RVNA GMT on the 45th day and in 1-year, 2-year, and 3-year in the Zagreb and Essen regimen group were 11.32 IU/ml, 1.69 IU/ml, 1.30 IU/ml, 1.30 IU/m and 13.18 IU/ml, 2.13 IU/ml, 1.87 IU/ml, 1.84 IU/m, respectively. There was no significant difference in the RVNA GMT levels at the same time point between the two regimen groups ( F=1.971, P=0.164). The RVNA GMT levels in the two regimen groups had the same trend of attenuation over time (time*group F=0.702, P=0.435). Retrospective study: The RVNA positive rates in 1-year, 2-year and 3-year after immunization in the Zagreb and Essen regimen group were 100%, 95%, 91.43%和94.73%, 86.21%, 87.5%, respectively. There was no statistically significant difference in the RVNA positive rates at the same time point between the two regimen groups ( P>0.05). The RVNA GMT in 1-year, 2-year, and 3-year groups after immunization in the Zagreb and Essen regimen group were 2.65 IU/ml, 2.03 IU/ml, 1.57 IU/ml和3.2 IU/ml, 2.58 IU/ml, 2.45 IU/ml, respectively. There was no significant difference in the RVNA GMT levels at the same time point between the two regimen groups ( P>0.05). Conclusions:The PVRV showed the same excellent immunogenicity and immune persistence after the vaccination with the Zagreb and Essen regimens.